Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carnitine-acylcarnitine translocase (CACT) is a mitochondrial inner membrane protein essential for the transport of long-chain fatty acylcarnitines into the mitochondrial matrix, where they undergo β-oxidation to produce energy. CACT operates as part of the carnitine shuttle system, exchanging acylcarnitines from the intermembrane space with free carnitine from the matrix in a 1:1 ratio. Deficiency or dysfunction of CACT leads to Carnitine-Acylcarnitine Translocase Deficiency (CACT deficiency), an autosomal recessive disorder caused by mutations in SLC25A20.
L-carnitine supplementation supports residual CACT function and helps in the excretion of acylcarnitines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carnitine-acylcarnitine translocase (CACT).